Current medical recommendations for semaglutide & breastfeeding As mentioned, the research into the risks of taking semaglutide while breastfeeding is ongoing
While this suggests cancer-type-specific mechanisms for VTE, device implantation and cancer therapies further modify coagulation status and increase the risk of CAT [147,148,149]
These conditions share complex etiologies and require long-term management strategies
This may result in: Diminished effectiveness Reduced pumps and anabolic response Need for longer off-cycles to reset receptor sensitivity To prevent this, most users limit LR3 cycles to 46 weeks , followed by an equal or longer break
In our experience, only a handful of patients have had these side effects
Ethosuximide: valproate may increase ethosuximide concentrations and lead to toxicity